Topics

Glioblastoma | Treatment | Targeted therapy

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy

□ OVERVIEW

□ ADAVOSERTIB

□ AFATINIB

□ ALECTINIB

□ ALISERTIB

□ APATINIB

□ APTAMERS

□ ATEZOLIZUMAB

■ BEVACIZUMAB

□ BOTENSILIMAB

□ BRAF-MEK-INHIBITORS

□ CILENGITIDE

□ DABRAFENIB

□ DASATINIB

□ DNA DAMAGE RESPONSE INHIBIT

□ DRUG SCREENING

□ EGFR INHIBITORS

□ ENTRECTINIB

□ ERDAFITINIB

□ GLUTAMATE SIGNALING INHIBITORS

□ IDASANUTLIN

□ IDO1 INHIBITORS

□ IPILIMUMAB

□ ISPINESIB

□ IVOSIDENIB

□ KHK2455

□ KINASE INHIBITORS

□ LAROTRECTINIB

□ LENVATINIB

□ LISAVANBULIN

□ ¹⁷⁷LU-PSMA

□ MARIZOMIB

□ MICROENV MODULATORS

□ MOGAMULIZUMAB

□ NANOPARTICLES

□ NAVTEMADLIN

□ NEUTROPHILS

□ NIMOTUZUMAB

□ NIVOLUMAB

□ OLAPARIB

□ PALBOCICLIB

□ PD-L1 TARGETED CANCER THERAPY

□ PEMBROLIZUMAB

□ PEMIGATINIB

□ PEXIDARTINIB

□ PRE-RADIATION TARGETED THERAPY

□ PROTON PUMP INHIBITORS

□ RADIOPHARMACEUTICALS

□ REGORAFENIB

□ RELATLIMAB

□ RINDOPEPIMUT

□ RO7428731

□ SACITUZUMAB GOVITECAN

□ SINTILIMAB

□ SOTORASIB

□ STEM CELL THERAPY

□ SUNITINIB

□ TELOMERASE-TARG THER

□ TEMSIROLIMUS

□ TEPOTINIB

□ TISLELIZUMAB

□ TOPOISOMERASE INHIBITORS

□ TRAMETINIB

□ VABAMETKIB

□ VELIPARIB

□ VEBRELTINIB

□ VEMURAFENIB

□ VISMODEGIB

□ VOLASERTIB